These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
542 related items for PubMed ID: 15953415
1. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. Neuron; 2005 Jun 16; 46(6):857-68. PubMed ID: 15953415 [Abstract] [Full Text] [Related]
2. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, Pfragner R, Schreiner E, Windisch M, Masliah E. J Neurosci Res; 2005 Apr 15; 80(2):247-59. PubMed ID: 15765523 [Abstract] [Full Text] [Related]
3. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ. Exp Neurol; 2002 May 15; 175(1):35-48. PubMed ID: 12009758 [Abstract] [Full Text] [Related]
4. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, Marr R, Masliah E. Gene Ther; 2004 Dec 15; 11(23):1713-23. PubMed ID: 15483670 [Abstract] [Full Text] [Related]
5. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Neurobiol Dis; 2009 Sep 15; 35(3):385-98. PubMed ID: 19505575 [Abstract] [Full Text] [Related]
6. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, Nussbaum RL. Neurobiol Aging; 2005 Jan 15; 26(1):25-35. PubMed ID: 15585343 [Abstract] [Full Text] [Related]
7. Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, Masliah E. J Neurochem; 2006 Aug 15; 98(4):1032-45. PubMed ID: 16895578 [Abstract] [Full Text] [Related]
8. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M, Matsumoto K, Nakamura A, Tada N, Kobayashi K, Iwatsubo T, Yoshimoto M. J Neurosci Res; 2007 Jun 15; 85(8):1819-25. PubMed ID: 17465029 [Abstract] [Full Text] [Related]
9. Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein. Choi JY, Park HJ, Seong YM, Choi EY, Min BR, Rhim H. Neurosci Lett; 2007 Jun 15; 397(1-2):53-8. PubMed ID: 16380207 [Abstract] [Full Text] [Related]
10. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Schell H, Hasegawa T, Neumann M, Kahle PJ. Neuroscience; 2009 Jun 02; 160(4):796-804. PubMed ID: 19272424 [Abstract] [Full Text] [Related]
11. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Yu S, Li X, Liu G, Han J, Zhang C, Li Y, Xu S, Liu C, Gao Y, Yang H, Uéda K, Chan P. Neuroscience; 2007 Mar 16; 145(2):539-55. PubMed ID: 17275196 [Abstract] [Full Text] [Related]
13. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Shirakashi Y, Kawamoto Y, Tomimoto H, Takahashi R, Ihara M. Acta Neuropathol; 2006 Dec 16; 112(6):681-9. PubMed ID: 16957925 [Abstract] [Full Text] [Related]
14. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions. Tsuchiya K, Tajima H, Kuwae T, Takeshima T, Nakano T, Tanaka M, Sunaga K, Fukuhara Y, Nakashima K, Ohama E, Mochizuki H, Mizuno Y, Katsube N, Ishitani R. Eur J Neurosci; 2005 Jan 16; 21(2):317-26. PubMed ID: 15673432 [Abstract] [Full Text] [Related]
15. Transgenic models of alpha-synuclein pathology: past, present, and future. Hashimoto M, Rockenstein E, Masliah E. Ann N Y Acad Sci; 2003 Jun 16; 991():171-88. PubMed ID: 12846986 [Abstract] [Full Text] [Related]
16. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. Lee FK, Wong AK, Lee YW, Wan OW, Chan HY, Chung KK. J Neurochem; 2009 Jul 16; 110(1):208-19. PubMed ID: 19457126 [Abstract] [Full Text] [Related]
17. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Gallardo G, Schlüter OM, Südhof TC. Nat Neurosci; 2008 Mar 16; 11(3):301-8. PubMed ID: 18297066 [Abstract] [Full Text] [Related]
18. Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Suzuki K, Iseki E, Togo T, Yamaguchi A, Katsuse O, Katsuyama K, Kanzaki S, Shiozaki K, Kawanishi C, Yamashita S, Tanaka Y, Yamanaka S, Hirayasu Y. Acta Neuropathol; 2007 Nov 16; 114(5):481-9. PubMed ID: 17653558 [Abstract] [Full Text] [Related]
19. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. Li W, Lee MK. J Neurochem; 2005 Jun 16; 93(6):1542-50. PubMed ID: 15935070 [Abstract] [Full Text] [Related]
20. Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Zhang L, Zhang C, Zhu Y, Cai Q, Chan P, Uéda K, Yu S, Yang H. Brain Res; 2008 Dec 09; 1244():40-52. PubMed ID: 18817762 [Abstract] [Full Text] [Related] Page: [Next] [New Search]